Curated news and analysis on clinical trials, drug approvals, and medical research.
A computational histology artificial intelligence platform can predict which of two chemotherapy regimens is more effective for individual pancreatic cancer patients, according to a study published in the Journal of Clinical Oncology.
The immuno-oncology market is projected to grow from $65.22 billion in 2025 to $170.19 billion by 2032, driven by checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, with North America commanding 43% market share.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
Researchers at the University of Bath have developed a bacterial system that produces, chemically stabilizes, and tests millions of peptide drug candidates inside living cells, identifying inhibitors of transcription factor CREB1 overactive in multiple cancers.
The global mRNA and next-generation vaccine platforms market is expected to grow from $39.69 billion in 2025 to $82.61 billion by 2030 at a 15.8% CAGR, driven by personalized medicine demand and infectious disease applications, while safety concerns and regulatory scrutiny continue.
The 2026 ASCO GU Symposium featured significant trial results in renal cell carcinoma, urothelial carcinoma, and prostate cancer, including data from LITESPARK-022, KEYNOTE-B15, SunRISE-2, and PEACE-3 studies.
U.S. Immigration and Customs Enforcement announced arrests of criminal illegal aliens convicted of sex crimes against children, drug trafficking, and gang activity. Nearly 70% of ICE arrests involve individuals charged or convicted of crimes in the U.S.
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
New research demonstrates blood-based biomarkers can predict testicular cancer recurrence and treatment outcomes, while separate study reveals long-term health risks vary by chemotherapy regimen in survivors.
At least 111 substances of unknown safety have been added to U.S. foods, drinks and supplements without alerting the FDA, exploiting a legal loophole in the "generally recognized as safe" standard, according to a new investigation.
Novo Nordisk announced a $506 million investment to expand its Athlone, Ireland manufacturing facility for oral GLP-1 drugs, following strong early uptake of Wegovy weight loss pills in the US market.
Insilico Medicine has formed a strategic partnership with Liquid AI to develop lightweight scientific foundation models for drug discovery and entered a drug development collaboration with China Medical System Holdings targeting CNS and autoimmune diseases.
Tempus AI and Merck announced an expanded multi-year collaboration to accelerate discovery and development of precision medicine biomarkers using AI and multimodal datasets, focusing on oncology and potentially broader therapeutic areas.
Scholar Rock plans to resubmit its biologics license application for apitegromab in spinal muscular atrophy following FDA reinspection of the Catalent Indiana fill-finish facility, with a U.S. launch anticipated in 2026.
Coya Therapeutics detailed plans for a Phase 2 trial of combination immunotherapy targeting neuroinflammation in ALS, following a four-patient study showing biomarker improvements and reported slowing of disease progression.
Amylyx Pharmaceuticals is advancing avexitide toward potential FDA approval for post-bariatric hypoglycemia, with Phase 3 LUCIDITY trial results expected in Q3 2026 and a cash runway extending into 2028.
ImmunityBio establishes wholly owned subsidiary in Saudi Arabia to distribute Anktiva for bladder and lung cancer across MENA region, following world's first lung cancer approval in the Kingdom less than a year after May 2025 meeting.
Major pharmaceutical and biotech companies are urging the Trump administration to withdraw two Medicare pricing proposals that would align U.S. drug prices with international benchmarks, arguing the mandatory models exceed government authority and threaten innovation.
Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.
The global cancer gene therapy market is projected to grow from $3.6 billion in 2023 to $16 billion by 2033 at a 16.1% CAGR, while the broader oncology market eyes $748 billion by 2035, driven by immunotherapy advances and targeted treatments.
